{
    "nct_id": "NCT03655678",
    "official_title": "A Phase 1/2/3 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects With Transfusion-Dependent β-Thalassemia",
    "inclusion_criteria": "* Diagnosis of transfusion-dependent β-thalassemia (TDT) as defined by\n\n  1. Documented homozygous β-thalassemia or compound heterozygous β-thalassemia including β-thalassemia/hemoglobin E (HbE). Participants can be enrolled based on historical data, but a confirmation of the genotype using the study central laboratory will be required before busulfan conditioning\n  2. History of at least 100 mL/kg/year or ≥10 units/year of packed RBC transfusions in the prior 2 years before signing the consent or the last rescreening for patients going through re-screening\n* Eligible for autologous stem cell transplant as per investigator's judgment\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 12 Years\nMust have maximum age of 35 Years",
    "exclusion_criteria": "* A willing and healthy 10/10 Human Leukocyte Antigen (HLA)-matched related donor is available per investigator's judgement\n* Prior allo-HSCT\n* Participants with associated α-thalassemia and >1 alpha deletion or alpha multiplications\n* Participants with sickle cell beta thalassemia variant\n* Clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by the investigator\n* White blood cell (WBC) count <3 × 10^9/L or platelet count <50 × 10^9/L not related to hypersplenism\n\nOther protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}